Add Formweb to your mobile device
Approved Formulary
Search results for:
silodosin
silodosin
Brand names: Rapaflo
| Form | Strength |
|---|---|
| CAPSULE, ORAL | 4 mg; 8 mg |
Display Selective a1-Adrenergic Blocking Agents Class:
12160412
Medication comments:
| 2023 American Geriatrics Society Beers Criteria® for potentially inappropriate medication use in older adults. | |
|---|---|
| Medication: | silodosin (Rapaflo) |
| Data are limited for selective peripheral alpha-1 blockers (e.g., tamsulosin, silodosin, and others) but may apply as well. | |
| Criteria 2: Potentially inappropriate medication use in older adults due to drug–disease or drug–syndrome interactions that may exacerbate the disease or syndrome. (Table 3) | |
| Drug(s) ⇆ disease or syndrome | selective peripheral alpha-1 blockers ⇄ Urinary incontinence (all types) in women |
| Rationale | Aggravation of incontinence. |
| Recommendation | Avoid in women. |
| Quality of evidence: Moderate, Strength of Recommendation: Strong | |
| Criteria 4: Potentially clinically important drug-drug interactions that should be avoided in older adults. (Table 5) | |
| Interacting drug(s) or class(es) | selective peripheral alpha-1 blockers ⇄ Loop diuretics |
| Risk Rationale | Increased risk of urinary incontinence in older women. |
| Recommendation | Avoid in older women, unless conditions warrant both drugs. |
| Quality of evidence: Moderate, Strength of Recommendation: Strong | |
Last updated: Sep. 19, 2025
- Look-Alike/Sound-Alike silodosin confused with sirolimus